Five Prime Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.fiveprime.com
Clinical Trials
26
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
FPT155 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04074759
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Scientia Clinical Research, Randwick, New South Wales, Australia
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
- Conditions
- Recurrent Bladder Cancer
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Registration Number
- NCT03801278
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Conditions
- Gastric Cancer
- Interventions
- Biological: BemarituzumabDrug: PlaceboDrug: Modified FOLFOX6
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT03694522
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸The Oncology Institute of Tuscon, Tucson, Arizona, United States
🇺🇸Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc, Greenbrae, California, United States
FPA150 in Patients With Advanced Solid Tumors
- Conditions
- Ovarian CancerBreast CancerEndometrial CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03514121
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCLA, Los Angeles, California, United States
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
- Conditions
- Gastrointestinal CancerGastric CancerGastrointestinal Cancer Metastatic
- Interventions
- Biological: BemarituzumabDrug: Modified FOLFOX6
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03343301
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Marin Cancer Care, Greenbrae, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
- Prev
- 1
- 2
- 3
- Next